Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.

Schrörs B, Lübcke S, Lennerz V, Fatho M, Bicker A, Wölfel C, Derigs P, Hankeln T, Schadendorf D, Paschen A, Wölfel T.

Oncotarget. 2017 Apr 25;8(17):28312-28327. doi: 10.18632/oncotarget.16048.

2.

Exome Sequencing to Predict Neoantigens in Melanoma.

Pritchard AL, Burel JG, Neller MA, Hayward NK, Lopez JA, Fatho M, Lennerz V, Wölfel T, Schmidt CW.

Cancer Immunol Res. 2015 Sep;3(9):992-8. doi: 10.1158/2326-6066.CIR-15-0088. Epub 2015 Jun 5.

3.

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T.

Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

PMID:
23051752
4.

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8. Epub 2005 Oct 24.

Supplemental Content

Support Center